Vanda Pharmaceuticals Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Novartis Ag

Vanda Pharmeceuticals, Inc.

Novartis Pharma Gmbh

Curt Douglas Wolfgang

Mihael Hristos Polymeropoulos

Paolo Baroldi

Ira H Pastan

Ulrich Brinkmann

Christian Lavedan

Byungkook Lee

Tapan K Bera

James Vincent

Deepak Phadke

John Joseph Feeney

Simona Volpi

George Vasmatzis

Gunther Birznieks

Magnus Essand

Sridhar Kudaravalli

Rosarelis Torres

Karen Mccullough

Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof. In one embodiment, the invention provides a method of preventing schizophrenic relapse in an individual diagnosed with schizophrenia, the method comprising: administering to the individual iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof at a daily dose between about 12 mg and about 16 mg following a period in which the individual's schizophrenia was stabilized.

Iloperidone for the treatment of schizophrenia

R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic.

Iloperidone metabolite for use in the treatment of psychiatric disorders

The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.

Method of treatment based on polymorphisms of the KCNQ1 gene

Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.

Method and composition for treating an alpha adrenoceptor-mediated condition

The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.

Methods for the administration of iloperidone

A method and composition for treating serotonin receptor-mediated conditions.

Method and composition for treating a serotonin receptor-mediated condition

The present invention relates to methods for treating a patient with iloperidone or a metabolite thereof, which patient is also being treated with fluoxetine, and lowering risk for QT prolongation.

A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.

Growing community of inventors

Germantown, MD, United States of America

Curt Douglas Wolfgang